Table 1. Characteristics of included studies.

Author name	Year	Setting	Groups	Sample size	Dose of favipiravir	Mean age in years	Males, %	Mild cases, %	Moderate cases, %
Bosaeed et al. [14]	2022	Multi-center	Favipiravir	112	First day: 1800 mg and 800 mg from day 2 onwards	36.5	67.10%	100%	0%
			Control	119
Chuah et al. [15]	2022	Multi-center	Favipiravir	250	First day: 1800 mg and 800 mg from day 2 onwards	62.5	48.40%	49.80%	50.20%
			Control	250
Holubar et al. [16]	2022	Single center	Favipiravir	59	First day: 1800 mg and 800 mg from day 2 onwards	43.2	42.24%	100%	0%
			Control	57
Khamis et al. [17]	2021	Single Center	Favipiravir	44	First day: 1600 mg and 600 mg from day 2 onwards	55	58%	NR	NR
			Control	45
Lou et al. [18]	2020	Single Center	Favipiravir	9	First day: 1600 mg and 600 mg from day 2 onwards	52.3	73.70%	NR	NR
			Control	10
McMohan et al. [19]	2022	Single center	Favipiravir	95	First day: 1800 mg and 800 mg from day 2 onwards	36	54.80%	NR	NR
			Control	95
Shinkai et al. [20]	2021	Single center	Favipiravir	107	First day: 1800 mg and 800 mg from day 2 onwards	46.3	66.70%	0%	100%
			Control	49
Udwadia et al. [11]	2021	Multi-center	Favipiravir	72	First day: 1800 mg and 800 mg from day 2 onwards	43.3	73.50%	60.50%	39.50%
			Control	75